ORGANOGENESIS HOLDINGS INC. - CLASS A

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

08 مايو 2025 16:05:01 بحسب Nasdaq GlobeNewswire

Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness

11 أبريل 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

07 أبريل 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

27 فبراير 2025 16:05:01 بحسب Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025

27 يناير 2025 07:30:00 بحسب Nasdaq GlobeNewswire

Organogenesis Expands Manufacturing Capacity to Support Future Growth

22 نوفمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Organogenesis Commends Final LCDs

15 نوفمبر 2024 09:25:44 بحسب Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results

12 نوفمبر 2024 16:05:01 بحسب Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

12 نوفمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

11 نوفمبر 2024 17:05:00 بحسب Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

16 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers

01 أكتوبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

04 سبتمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results

08 أغسطس 2024 16:05:01 بحسب Nasdaq GlobeNewswire

Organogenesis Shares ReNu® Program Update

08 أغسطس 2024 16:04:00 بحسب Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

15 يوليو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference

06 يونيو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results

09 مايو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

02 مايو 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

16 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire